Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
Casirivimab
Spike protein
Emergency use authorization Experimental Antiviral Jan/23/2023
Imdevimab
Spike protein
Emergency use authorization Experimental Antiviral Jan/23/2023
T cells
Spike protein
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Jan/18/2023
Remdesivir
Spike protein
Approved by FDA Experimental Antiviral Jan/18/2023
Anti-spike nanobody-IFN-β conjugated exosomes
Spike protein
Potential treatment - pre-clinical evidence Experimental Antiviral Sep/26/2022
Exosomal vaccine
Spike protein
Potential treatment - pre-clinical evidence Experimental Vaccine Jul/29/2022
Sotrovimab
Spike protein
Emergency use authorization Experimental Antiviral Jul/14/2022
Nirmatrelvir
Spike protein
Emergency use authorization Experimental Antiviral Jun/23/2022
Bamlanivimab
Spike protein
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
Etesevimab
Spike protein
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
S309
Spike protein
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/22/2022
Ad26.COV2.S
Spike protein
Emergency use authorization Experimental Vaccine Jun/22/2022
BNT162b2
Spike protein
Approved by FDA Experimental Vaccine Jun/22/2022
mRNA-1273
Spike protein
Emergency use authorization Experimental Vaccine Jun/22/2022
Cilgavimab
Spike protein
Emergency use authorization Experimental Antiviral Jun/18/2022
Tixagevimab
Spike protein
Emergency use authorization Experimental Antiviral Jun/18/2022
Bebtelovimab
Spike protein
Emergency use authorization Experimental Antiviral Jun/18/2022
REGEN-COV
Spike protein
Emergency use authorization Experimental Antiviral Jun/03/2022
Convalescent plasma
Spike protein
Emergency use authorization Experimental Antiviral May/16/2022
ACE2‐Fc
Spike protein
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/26/2022